Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Nektar Therapeutics ( (NKTR) ).
At the Annual Meeting of Stockholders held on May 23, 2025, Nektar Therapeutics announced the election of new board members and approved several key proposals. These included amendments to increase authorized shares and implement a reverse stock split, as well as the ratification of Ernst & Young LLP as the independent accounting firm for 2025. These decisions are expected to impact the company’s strategic direction and shareholder value.
The most recent analyst rating on (NKTR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics is currently under financial pressure due to declining revenue and profitability issues, reflected in a low financial performance score. While the company has a strong cash position and is making advancements in its drug pipeline, the risks from litigation and financial distress weigh heavily. The stock’s technical analysis and valuation are also concerning, leading to an overall score indicating caution.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a Delaware-based company operating in the biopharmaceutical industry, focusing on the development of innovative drug candidates for various medical needs.
Average Trading Volume: 2,065,893
Technical Sentiment Signal: Strong Sell
Current Market Cap: $125.5M
For detailed information about NKTR stock, go to TipRanks’ Stock Analysis page.